NCT03361735 2026-04-09
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
Clinical Trials
36 trialsNCT06654336 2026-03-13
RATIONAL
Ontario Clinical Oncology Group (OCOG)
Phase 2 Recruiting
NCT07142551 2026-03-11
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT07455903 2026-03-06
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Baptist Health South Florida
Phase 2 Not yet recruiting
NCT05617885 2026-02-27
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT01786265 2026-02-20
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06305598 2026-02-19
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT02274779 2026-02-13
OLIGOPELVIS
Institut Cancerologie de l'Ouest
Phase 2 Completed
NCT03902951 2026-02-05
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04734730 2026-01-28
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT03070886 2026-01-14
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
Phase 2/3 Completed
NCT06059118 2026-01-14
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT05873192 2025-12-23
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06922318 2025-09-17
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT04249154 2025-06-25
PROMPT
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Recruiting
NCT02903368 2025-06-13
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00544830 2025-05-07
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03703778 2025-05-06
READT
Chinese University of Hong Kong
Active not recruiting
NCT04302454 2025-04-04
ADOPT
University Medical Center Groningen
Phase 3 Active not recruiting
NCT06855589 2025-03-04
PCS-XII
Charles LeMoyne Hospital
Phase 3 Not yet recruiting
NCT02588404 2024-12-10
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
Sir Mortimer B. Davis - Jewish General Hospital
Withdrawn
NCT02685397 2024-12-04
PCS IX
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2/3 Active not recruiting
NCT01442246 2024-09-19
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.
UNICANCER
Phase 3 Active not recruiting
NCT04239599 2022-09-29
RCT-PHART2
Sunnybrook Health Sciences Centre
Phase NA Unknown
NCT04585932 2021-01-20
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02168062 2020-07-23
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT03380806 2020-06-04
PBS
Juravinski Cancer Center
Phase 2 Unknown
NCT00937768 2019-12-27
Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Mayo Clinic
Phase 2 Terminated
NCT01136226 2018-10-24
Eligard
Chesapeake Urology Research Associates
Phase 4 Completed
NCT00223665 2018-08-07
IAS
University of Washington
Phase 2 Completed
NCT00225420 2017-06-01
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT01642732 2017-05-30
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT00170157 2017-05-15
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT00452556 2014-03-19
The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study
Nova Scotia Cancer Centre
Phase 2 Unknown
NCT01344564 2013-03-18
Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide
Urology of Virginia
Phase NA Completed